Organigram (OGI) Scheduled to Post Quarterly Earnings on Tuesday

Organigram (NASDAQ:OGIGet Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Organigram (NASDAQ:OGIGet Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). Organigram had a negative net margin of 173.48% and a negative return on equity of 30.94%. The firm had revenue of $26.78 million for the quarter, compared to analysts’ expectations of $28.61 million. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Stock Down 2.2 %

NASDAQ:OGI opened at $1.76 on Thursday. The company’s 50 day moving average price is $2.05 and its 200-day moving average price is $1.69. Organigram has a 52 week low of $0.97 and a 52 week high of $2.91. The stock has a market cap of $181.93 million, a price-to-earnings ratio of -2.20 and a beta of 1.07.

Analyst Ratings Changes

Separately, Alliance Global Partners upgraded shares of Organigram from a “neutral” rating to a “buy” rating in a report on Monday, April 15th.

View Our Latest Report on Organigram

About Organigram

(Get Free Report)

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

See Also

Earnings History for Organigram (NASDAQ:OGI)

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.